Epidemiology Practice Questions

Q: Cigarette smoking increases the risk of all the following diseases except?

Primary pulmonary hypertension. **Explanation:** The correct answer is **Primary Pulmonary Hypertension (PPH)**, now more commonly referred to as Idiopathic Pulmonary Arterial Hypertension (IPAH). **1. Why Primary Pulmonary Hypertension is the correct answer:** While cigarette smoking is the leading cause of **Secondary Pulmonary Hypertension** (due to chronic hypoxia and COPD/emphysema), it is not a recognized risk factor for **Primary Pulmonary Hypertension**. PPH is a rare disease of the small pulmonary arteries characterized by vascular remodeling, often linked to genetic mutations (e.g., BMPR2) or specific drugs/toxins (e.g., appetite suppressants), but not directly to tobacco smoke. **2. Analysis of Incorrect Options:** * **Pancreatic Carcinoma:** Smoking is a well-established risk factor for pancreatic cancer, accounting for approximately 20-25% of cases. Carcinogens from tobacco reach the pancreas via the bloodstream or bile. * **Cerebrovascular Accident (CVA):** Smoking is a major modifiable risk factor for stroke. It promotes atherosclerosis, increases platelet aggregation, and causes endothelial dysfunction, doubling the risk of ischemic stroke. * **Sudden Infant Death Syndrome (SIDS):** Maternal smoking during pregnancy and secondhand smoke exposure after birth are among the strongest preventable risk factors for SIDS. **Clinical Pearls for NEET-PG:** * **Smoking and Cancers:** Smoking is linked to cancers of the lung, larynx, oral cavity, esophagus, bladder, kidney, pancreas, and cervix. * **Buerger’s Disease (Thromboangiitis obliterans):** This is the most specific vascular disease associated with heavy smoking in young males. * **Protective Effect:** Interestingly, smoking is associated with a *decreased* risk of **Ulcerative Colitis** and **Endometrial Cancer** (due to anti-estrogenic effects), though these are rare exceptions to its overall toxicity.

Q: What is the recommended threshold for parasite prevalence (API) for initiating Malaria Mass Drug Administration?

Greater than 2. **Explanation:** In the context of Malaria control and elimination strategies, the **Annual Parasite Incidence (API)** is the most common indicator used to measure the malaria burden in a population. It is defined as the number of confirmed cases per 1,000 population per year. **Why Option B is Correct:** According to the National Framework for Malaria Elimination (NFME) in India and WHO guidelines, an **API > 2** is the critical threshold used to categorize "High Burden" areas (Category 3). In these high-transmission settings, **Mass Drug Administration (MDA)** or targeted mass treatments are recommended as a rapid intervention to reduce the parasite reservoir in the community, interrupt transmission, and prevent outbreaks. **Analysis of Incorrect Options:** * **Option A (API > 5):** While an API > 5 indicates very high transmission, the intervention threshold for aggressive measures like MDA is lower (at 2) to ensure early containment before the burden reaches such high levels. * **Option C (15) and D (25):** These values are significantly higher than the standard epidemiological thresholds used for public health decision-making in malaria elimination programs. An API of 15-25 would indicate a severe epidemic state rather than a strategic threshold for initiating MDA. **High-Yield Clinical Pearls for NEET-PG:** * **API Formula:** (Total number of positive slides / Total population) × 1000. * **API 10%** to ensure adequate surveillance. * **SPR (Slide Positivity Rate):** A more sensitive indicator of recent changes in transmission than API. * **MDA Drugs:** Usually involves a combination of an ACT (Artemisinin-based Combination Therapy) and a single dose of Primaquine (as a gametocytocide).

Q: In a population of 100,000 people, 10 men met all the criteria for a severely debilitating disease over a 1-year period. An additional 90 men demonstrated mild symptoms but failed to meet the full criteria. Assuming a male:female ratio of 1:1 in this population, what is the male risk of being diagnosed with this disease?

0.02%. ### Explanation **1. Understanding the Correct Answer (B: 0.02%)** To calculate the **Risk** (Incidence Proportion), we use the formula: $$\text{Risk} = \frac{\text{Number of new cases during a specific period}}{\text{Population at risk during that period}} \times 100$$ * **Numerator:** Only the **10 men** who met the full diagnostic criteria are considered "cases." The 90 men with mild symptoms are excluded as they do not meet the case definition. * **Denominator:** The question asks for the **male risk**. Since the total population is 100,000 and the male:female ratio is 1:1, the population of men (at risk) is **50,000**. * **Calculation:** $(10 / 50,000) \times 100 = 0.02\%$. **2. Analysis of Incorrect Options** * **A (0.01%):** This is the result if you use the total population (100,000) instead of the male-only population (50,000). * **C (0.20%):** This occurs if you incorrectly include the 90 symptomatic men as cases $(100 / 50,000 \times 100)$. In epidemiology, a "case" must strictly meet the predefined criteria. * **D (0.40%):** This is a mathematical error likely derived from doubling the incorrect calculation in Option C. **3. NEET-PG High-Yield Pearls** * **Case Definition:** Always stick to the formal criteria provided. Sub-clinical or "mild" cases that don't meet criteria are excluded from the numerator but remain in the denominator. * **Denominator Selection:** Pay close attention to whether the question asks for the "Total Population Risk" or a "Specific Group Risk" (e.g., gender-specific or age-specific). * **Incidence vs. Prevalence:** Risk (Incidence) measures **new** cases over a period, whereas Prevalence measures **all** existing cases at a point in time. * **Mid-year Population:** In large-scale community medicine problems, if the population at risk changes, the mid-year population is typically used as the denominator.

Q: Ability of an organism to induce clinically apparent illness is known as:

Pathogenicity. **Explanation:** The correct answer is **Pathogenicity**. In epidemiology, the interaction between an agent and a host is measured by specific parameters that define the agent's behavior. 1. **Why Pathogenicity is correct:** Pathogenicity is defined as the ability of an infectious agent to produce **clinically apparent illness** in a susceptible host. It is calculated as the ratio of the number of persons developing clinical disease to the total number of persons exposed to the infection. It reflects the "quality" of the organism to cause symptoms rather than just an infection. 2. **Why other options are incorrect:** * **Infectivity:** This is the ability of an agent to enter, survive, and **multiply** in a host. It is measured by the secondary attack rate. An organism can have high infectivity (spread easily) but low pathogenicity (cause mild or no symptoms, e.g., Poliovirus). * **Virulence:** This refers to the **severity** of the clinical disease produced. It is the proportion of clinical cases that result in severe manifestations or death. A common measure of virulence is the **Case Fatality Rate (CFR)**. * **Viability:** This is the ability of an organism to survive in the external environment (outside the host). **High-Yield Clinical Pearls for NEET-PG:** * **Iceberg Phenomenon:** Pathogenicity determines how much of the "iceberg" is above the water (visible clinical cases). * **Infectivity** = (Infected / Exposed) * **Pathogenicity** = (Clinically ill / Infected) * **Virulence** = (Severe cases or Deaths / Clinically ill) * **Example:** Rabies has extremely high pathogenicity and virulence, whereas Polio has high infectivity but very low pathogenicity (95% of cases are subclinical).

Q: Case Fatality Rate (CFR) of Rabies is:

100%. ### Explanation **1. Understanding the Correct Answer (C. 100%)** Case Fatality Rate (CFR) is a measure of the **virulence** or killing power of a disease, calculated as the number of deaths divided by the total number of diagnosed cases. Rabies is unique in clinical medicine because once the virus enters the central nervous system and symptoms appear, it is considered **universally fatal**. There is no effective cure for clinical rabies, and death typically occurs within 2 to 10 days due to respiratory paralysis or cardiac arrest. Therefore, the CFR is mathematically and clinically 100%. **2. Analysis of Incorrect Options (A, B, D)** Options A (80%), B (90%), and D (95%) are incorrect because they suggest a possibility of survival or recovery after the onset of symptoms. While modern intensive care (e.g., the Milwaukee Protocol) has attempted to treat symptomatic patients, these cases are extreme statistical outliers and have not successfully altered the established 100% CFR in medical literature. **3. NEET-PG High-Yield Clinical Pearls** * **Definition of CFR:** It is a ratio (expressed as a percentage), not a rate, as it does not involve a time component in the denominator. * **Indicator of Virulence:** CFR is the best indicator of the virulence of an infectious agent. * **Rabies Prevention:** While the CFR is 100%, the disease is **100% preventable** through timely Post-Exposure Prophylaxis (PEP), including wound washing, Rabies Vaccine, and Rabies Immunoglobulin (RIG). * **Incubation Period:** Typically 1–3 months but can range from 1 year. * **Diagnostic Hallmark:** Presence of **Negri bodies** (intracytoplasmic inclusion bodies) in the hippocampus and cerebellum (post-mortem).

Q: Maternal mortality refers to maternal deaths from causes related to or aggravated by pregnancy and its management during which period?

Pregnancy, childbirth, or the first 42 days after delivery. **Explanation:** The definition of **Maternal Mortality**, as established by the WHO (ICD-10), refers to the death of a woman while pregnant or within **42 days (6 weeks)** of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes. **Why Option D is Correct:** The 42-day period (6 weeks) corresponds to the **puerperium**, the time required for the mother’s reproductive organs to return to their non-pregnant state. Most physiological changes and potential complications (like secondary PPH or puerperal sepsis) occur within this window. **Why other options are incorrect:** * **Option A (7 days):** This timeframe is typically associated with "Early Neonatal Mortality," not maternal mortality. * **Option B (14 days):** This is an arbitrary number with no specific epidemiological significance in maternal health definitions. * **Option C (28 days):** This defines the "Neonatal period." While some maternal complications occur here, the standard definition extends to 42 days to capture late postpartum complications. **High-Yield NEET-PG Pearls:** 1. **Late Maternal Death:** Death from direct or indirect obstetric causes more than 42 days but less than **one year** after termination of pregnancy. 2. **Maternal Mortality Ratio (MMR):** Calculated as (Total Maternal Deaths / Total **Live Births**) × 100,000. Note: It is a *ratio*, not a rate, because the denominator (live births) is not the actual population at risk (all pregnant women). 3. **Most Common Cause:** Globally and in India, the leading cause of maternal mortality is **Obstetric Hemorrhage** (specifically PPH).

Q: Calculate the prevalence if the incidence is 2 cases per 1,000 population per year and the mean duration of the disease is 4 years.

8 cases per 1,000 population. ### Explanation **1. Understanding the Correct Answer (Option A)** The relationship between prevalence, incidence, and duration of a disease is expressed by the fundamental epidemiological formula: **Prevalence (P) = Incidence (I) × Mean Duration (D)** This formula is applicable when the disease is in a "steady state" (i.e., incidence and duration remain constant over time). * **Given:** Incidence (I) = 2 cases per 1,000 population/year; Duration (D) = 4 years. * **Calculation:** $P = 2 \times 4 = 8$ cases per 1,000 population. Prevalence represents the total burden of disease in a population at a specific point in time, which naturally increases if the disease lasts longer, even if the rate of new cases (incidence) remains low. **2. Analysis of Incorrect Options** * **Option B (2 cases):** This simply repeats the incidence. Prevalence only equals incidence if the duration of the disease is exactly one year. * **Option C (0.5 cases):** This results from dividing incidence by duration ($2 \div 4$). This is mathematically incorrect for this relationship. * **Option D (32 cases):** This is an arbitrary calculation (likely $2 \times 4^2$) and has no basis in epidemiological formulas. **3. NEET-PG High-Yield Pearls** * **Steady State Condition:** The formula $P = I \times D$ assumes that the population is stable and that the rates of recovery and death are constant. * **Impact of Medical Progress:** If a new drug improves survival but does not cure the disease (e.g., Insulin for Diabetes or ART for HIV), the **Duration (D)** increases, which subsequently increases the **Prevalence (P)**, even if the **Incidence (I)** remains unchanged. * **Incidence vs. Prevalence:** Remember, Incidence is a **rate** (new cases), while Prevalence is a **proportion** (all existing cases). Incidence is best for studying etiology; Prevalence is best for administrative planning.

Q: The usefulness of a screening test in a community depends on its?

Sensitivity. **Explanation:** The primary objective of a **screening test** in a community is to detect as many cases of a disease as possible in an early, asymptomatic stage. Therefore, the most important attribute for a screening test's usefulness is its **Sensitivity**. 1. **Why Sensitivity is Correct:** Sensitivity is the ability of a test to correctly identify those with the disease (True Positives). In public health, a screening test must have high sensitivity to ensure a "wide net" is cast, minimizing **False Negatives**. If a screening test misses cases, the opportunity for early intervention is lost, defeating the purpose of the program. 2. **Why other options are incorrect:** * **Specificity:** This is the ability to identify those without the disease. While important to avoid over-investigation, high specificity is more critical for **Diagnostic tests** to confirm a disease, rather than screening tests. * **Reliability (Precision):** This refers to the consistency of the test results when repeated. While necessary for any valid test, it does not determine the clinical utility of finding cases in a population. * **Predictive Value:** Positive Predictive Value (PPV) indicates the probability that a person with a positive test actually has the disease. While PPV determines the *clinical yield* of a screening program, it is heavily dependent on the **prevalence** of the disease in the community, rather than being an inherent property of the test's usefulness in initial detection. **High-Yield NEET-PG Pearls:** * **Screening Test:** High Sensitivity (to rule out disease/minimize False Negatives). * **Diagnostic Test:** High Specificity (to rule in disease/minimize False Positives). * **Sensitivity** is also known as the **True Positive Rate**. * The **Predictive Value** of a test is the most important parameter for a clinician when interpreting a result for an individual patient.

Q: Which is the best study design for assessing a new disease with no etiological hypothesis?

Descriptive epidemiology. ### Explanation **Why Descriptive Epidemiology is the correct answer:** Descriptive epidemiology is the **first step** in any epidemiological investigation, especially when dealing with a new or unknown disease. Its primary purpose is to describe the occurrence of the disease in terms of **Time, Place, and Person**. Since there is "no etiological hypothesis" at the onset, descriptive studies (like case reports or case series) are essential to observe patterns and **formulate a hypothesis**. Analytical studies can only be conducted once a hypothesis exists to be tested. **Why the other options are incorrect:** * **Cohort Study (A):** This is an analytical study used to test a hypothesis by moving from cause to effect. It requires a pre-defined exposure to study, which is impossible if the etiology is unknown. * **Case-Control Study (B):** This is an analytical study used to test a hypothesis by moving from effect to cause. It requires knowing which potential risk factors to investigate. * **Randomized Control Trial (C):** This is an experimental study used to test the efficacy of a drug or intervention. It is the final stage of research and cannot be performed without understanding the disease mechanism. **High-Yield NEET-PG Pearls:** * **Sequence of Investigation:** Descriptive Study (Hypothesis Formulation) → Analytical Study (Hypothesis Testing) → Experimental Study (Hypothesis Confirmation). * **Descriptive Epidemiology** answers: Who? Where? When? * **Analytical Epidemiology** answers: Why? How? * For **rare diseases**, the study of choice is a **Case-Control Study**. * For **rare exposures**, the study of choice is a **Cohort Study**.

Question 1

Cigarette smoking increases the risk of all the following diseases except?

Accepted Answer

Primary pulmonary hypertension

Answer

Pancreatic carcinoma

Answer

Cerebrovascular accident

Answer

Sudden infant death syndrome

Question 2

What is the recommended threshold for parasite prevalence (API) for initiating Malaria Mass Drug Administration?

Accepted Answer

Greater than 2

Answer

Greater than 5

Answer

15

Answer

25

Question 3

In a population of 100,000 people, 10 men met all the criteria for a severely debilitating disease over a 1-year period. An additional 90 men demonstrated mild symptoms but failed to meet the full criteria. Assuming a male:female ratio of 1:1 in this population, what is the male risk of being diagnosed with this disease?

Accepted Answer

0.02%

Answer

0.01%

Answer

0.20%

Answer

0.40%

Question 4

Ability of an organism to induce clinically apparent illness is known as:

Accepted Answer

Pathogenicity

Answer

Infectivity

Answer

Virulence

Answer

Viability

Question 5

Case Fatality Rate (CFR) of Rabies is:

Accepted Answer

100%

Answer

80%

Answer

90%

Answer

95%

Question 6

Maternal mortality refers to maternal deaths from causes related to or aggravated by pregnancy and its management during which period?

Accepted Answer

Pregnancy, childbirth, or the first 42 days after delivery

Answer

Pregnancy, childbirth, or the first seven days after delivery

Answer

Childbirth or the first fourteen days after delivery

Answer

The first 28 days after delivery

Question 7

Calculate the prevalence if the incidence is 2 cases per 1,000 population per year and the mean duration of the disease is 4 years.

Accepted Answer

8 cases per 1,000 population

Answer

2 cases per 1,000 population

Answer

0.5 cases per 1,000 population

Answer

32 cases per 1,000 population

Question 8

Which of the following statements is true about monitoring?

Accepted Answer

Monitoring involves the analysis of measurements to detect changes in health status.

Answer

Monitoring is a broader concept.

Answer

Feedback is a component of monitoring.

Answer

Monitoring helps in detecting missed cases.

Question 9

The usefulness of a screening test in a community depends on its?

Accepted Answer

Sensitivity

Answer

Specificity

Answer

Reliability

Answer

Predictive value

Question 10

Which is the best study design for assessing a new disease with no etiological hypothesis?

Accepted Answer

Descriptive epidemiology

Answer

Cohort study

Answer

Case control study

Answer

Randomized control trial

Epidemiology — MCQs

Epidemiology — MCQs

On this page

Practice by Chapter

Want unlimited practice?